10 terminated, 8 active not recruiting, 7 recruiting, 6 completed. 21 Phase 1, 19 Phase 2, 1 Not applicable.
Follow Recurrent Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent Acute Lymphoblastic Leukemia trials Research Report on Recurrent Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-04-28 | 2026-05-19 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-06-05 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab - CD19 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 36 | 2019-08-02 | 2025-05-30 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 22 | 2018-02-08 | 2026-08-19 |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin - CD22 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-11-30 | 2021-04-12 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-05-20 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
Showing 20 of 35. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (35) · Leukemia, Myeloid, Acute (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Leukemia, Biphenotypic, Acute (10) · Blast Crisis (9) · Myelodysplastic Syndromes (9) · Burkitt Lymphoma (7) · Hematologic Neoplasms (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Myelomonocytic, Chronic (7) · Lymphoma, Non-Hodgkin (6) · Hodgkin Disease (5) · Leukemia, Myeloid, Accelerated Phase (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Myelodysplastic-Myeloproliferative Diseases (4)
Hematologic Diseases (35) · Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphatic Diseases (35) · Neoplasms (35) · Neoplasms by Histologic Type (35) · Leukemia (34) · Leukemia, Lymphoid (34) · Lymphoproliferative Disorders (34) · Leukemia, Myeloid (23) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Bone Marrow Diseases (21) · Chronic Disease (21)
Cyclophosphamide (13) · Vincristine (8) · fludarabine phosphate (8) · Cytarabine (7) · Methotrexate (7) · merphos (7) · CT-P10 (6) · Rituximab (6) · Specimen Handling (6) · Biopsy (5) · Calcium Dobesilate (5) · Dexamethasone (5) · Mycophenolic Acid (5) · Prednisone (5) · auricularum (5)
M.D. Anderson Cancer Center (14) · Fred Hutchinson Cancer Center (6) · City of Hope Medical Center (4) · National Cancer Institute (NCI) (2) · OHSU Knight Cancer Institute (2) · University of Washington (2) · Children's Oncology Group (1) · Ohio State University Comprehensive Cancer Center (1) · St. Jude Children's Research Hospital (1) · Sumithira Vasu (1) · University of Southern California (1)
United States (34) · Canada (1)
Elias Jabbour (3) · Elizabeth Krakow (2) · Ibrahim Aldoss (2) · Sumithira Vasu, MD (2) · Tapan M Kadia (2) · Akil Merchant, MD (1) · Anjali S Advani (1) · Brenda M. Sandmaier (1) · Chitra Hosing (1) · David Maloney (1) · Elias Jabbour, MD (1) · Farhad Ravandi-Kashani (1) · Farhad Ravandi-Kashani, MD (1) · Gautam Borthakur (1) · Ibrahim Aldoss, MD (1)
PMID 20466853, PMID 27410923, PMID 30335787, PMID 32478814, PMID 32692850, PMID 33357452, PMID 33720354, PMID 35007144, PMID 35622074, PMID 36322825, PMID 36402146, PMID 36841758, PMID 36873868, PMID 37611156, PMID 38683966, PMID 39028925, PMID 39863139, PMID 40369607, PMID 41671463, PMID 42341322
P30CA015704 (4), P30CA016672 (3), P01CA078902 (2), P01CA018029 (1), P30CA006516 (1), P30CA014089 (1), P30CA033572 (1), R01CA114536 (1), R01CA183559 (1), R01CA276374 (1), R01HL121568 (1), R21CA159265 (1), U01CA062490 (1), U10CA180886 (1), U10CA180888 (1)